Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab as the Adjuvant Treatment of HER2 Positive Patients Following Neoadjuvant Chemotherapy

NCT04302441 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04302441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04302441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab as the Adjuvant Treatment of HER2 Positive Patients Following Neoadjuvant Chemotherapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
November 10, 2016
Completion date
June 30, 2021
Enrollment
550 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer